

Senegal

Population 2015

15 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	3.4 (2.1–5.2)	23 (14–34)
Mortality (HIV+TB only)	0.41 (0.16–0.77)	2.7 (1–5.1)
Incidence (includes HIV+TB)	21 (14–30)	139 (90–198)
Incidence (HIV+TB only)	1.4 (0.92–2.1)	9.5 (6.1–14)
Incidence (MDR/RR-TB)**	0.41 (0.25–0.57)	2.7 (1.7–3.8)

Estimated TB incidence by age and sex (thousands)*, 2015

	0-14 years	> 14 years	Total
Females	1.3 (0.5–2.2)	7.3 (3.3–11)	8.6 (3.8–14)
Males	1.6 (0.95–2.2)	11 (7.3–14)	12 (8.2–16)
Total	2.9 (1.9–3.9)	18 (13–23)	21 (14–30)

TB case notifications, 2015

Total cases notified	13 599
Total new and relapse	13 300
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	83%
- % pulmonary	88%
- % bacteriologically confirmed among pulmonary	84%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	63% (44–98)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.19 (0.1–0.32)

TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive	763	7%
- on antiretroviral therapy	726	95%

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			280 (180–370)
Estimated % of TB cases with MDR/RR-TB	0.9% (0.24–1.6)	19% (12–25)	
% notified tested for rifampicin resistance	44%	170%	7 322
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 78, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: , XDR-TB:	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	87%	13 226
Previously treated cases, excluding relapse, registered in 2014	79%	264
HIV-positive TB cases, all types, registered in 2014	71%	481
MDR/RR-TB cases started on second-line treatment in 2013		
XDR-TB cases started on second-line treatment in 2013		

TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment	35%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2016

National TB budget (US\$ millions)	11
Funding source: 8% domestic, 26% international, 66% unfunded	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




Incidence
Notified (new and relapse)
Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



New and relapse
Retreatment, excluding relapse
HIV-positive MDR/RR-TB XDR-TB

Total budget (US\$ millions)

